Nexentis Technologies Inc. (NASDAQ: NXTS) Advances Drug Discovery with MitoCareX Bio Milestone

Expert Analysis Nexentis Technologies Inc. (NASDAQ: NXTS) has demonstrated a significant advancement in its pharmaceutical research capabilities through its subsidiary, MitoCareX Bio Ltd. The development of an optimized hit molecule represents a critical step forward in the company’s drug discovery efforts, potentially accelerating the path toward pre-clinical studies. This progress not only enhances Nexentis’ research profile but may also open avenues for future therapeutic applications. The milestone achieved by MitoCareX…

Read More >>

Charlie’s Holdings (OTCQB: CHUC) Expands California Distribution with SBX 25K Launch

Expert Analysis Charlie’s Holdings (OTCQB: CHUC) continues to strengthen its foothold in the California market with a strategic product rollout backed by regulatory approval. As the only company authorized on California’s Unflavored Tobacco List for four distinct modern disposable products, Charlie’s Holdings demonstrates its ability to navigate complex compliance landscapes effectively. This positions them uniquely among competitors in the tobacco and vaping sector, enhancing their market differentiation. The company’s authorization…

Read More >>

Artificial Intelligence Technology Solutions (OTC: AITX) Introduces SCANNA to Enhance Security with Existing Cameras

Expert Analysis Artificial Intelligence Technology Solutions (OTC: AITX) is leveraging its expertise in AI-driven security solutions by launching SCANNA, an innovative platform designed to enhance security using existing camera infrastructure. This strategic move positions Artificial Intelligence Technology Solutions (OTC: AITX) at the forefront of AI intelligent security operations, streamlining how organizations harness technology for safety. By integrating SCANNA, companies can accelerate their adoption of smart security measures without the need…

Read More >>

Autonomix Medical (NASDAQ: AMIX) Highlights Pancreatic Cancer Pain Data at EuroPCR 2026

Market Overview Autonomix Medical, Inc. (NASDAQ: AMIX) continues to capture attention in the medical device sector with its cutting-edge nerve-targeted therapies. As the company advances its innovative transvascular nerve-targeting platform, investors and industry watchers are noting its increasing relevance in treating complex conditions such as pancreatic cancer pain. This backdrop sets the stage for upcoming important presentations at a major industry event. The stock’s positioning aligns with growing interest in…

Read More >>

Provectus Biopharmaceuticals (OTCQB: PVCT) Reports Anti-Tumor Activity of Oral PV-10 in Bladder Cancer Study

Expert Analysis Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) continues to demonstrate promising progress in its investigational therapy portfolio with data highlighting the anti-tumor effects of its proprietary PV-10 compound. This preclinical evaluation involving oral administration of PV-10 explores a novel approach to targeting bladder cancer, a condition with significant unmet medical need. The use of an immunologically humanized mouse model provides valuable insight into the potential efficacy of PV-10, both as…

Read More >>

Outdoor Holding Company (NASDAQ: POWW) Declares Preferred Stock Dividend

Key Developments Outdoor Holding Company (NASDAQ: POWW), known for owning GunBroker.com and producing high-performance ammunition, announced a cash dividend for its Series A Cumulative Redeemable Perpetual Preferred Stock holders. Those recorded as shareholders by June 1, 2026, are set to receive this dividend. The dividend amount will be $0.546875 per share, and the payment is scheduled for June 15, 2026. This move highlights the company’s commitment to providing continued value…

Read More >>

Terra Innovatum Global N.V. (NASDAQ: NKLR) Secures Cooling Solution for SOLO™ Reactor

Key Developments Terra Innovatum Global N.V. (NASDAQ: NKLR) has announced a strategic supply agreement with SPG Dry Cooling to deliver a water-independent cooling solution for its SOLO™ Reactor technology. This collaboration aims to enhance the operational efficiency of the SOLO™ Reactor by ensuring reliable cooling without the need for traditional water resources. The agreement reflects Terra Innovatum Global N.V.’s commitment to advancing sustainable and resource-efficient technologies. Implementing SPG Dry Cooling’s…

Read More >>

Core AI Holdings (NASDAQ: CHAI) Announces Record Revenue Growth and Strategic AI Focus

Market Overview Core AI Holdings (NASDAQ: CHAI) experienced a remarkable fiscal year ended December 31, 2025, highlighted by a substantial surge in revenue growth. The company reported a record 59% increase, signaling a strong market response to its evolving business model. This notable performance reflects the broader investor enthusiasm for AI technology enterprises and their potential to revolutionize industries. During this period, Core AI Holdings (NASDAQ: CHAI) navigated significant shifts…

Read More >>

FG Nexus Inc. (NASDAQ: FGNX) Announces Quarterly Dividend on Preferred Stock

Key Developments FG Nexus Inc. (NASDAQ: FGNX) has declared a quarterly cash dividend on its 8.00% Cumulative Preferred Stock, Series A. This announcement confirms the company’s commitment to providing consistent returns to its preferred shareholders. The declaration demonstrates FG Nexus Inc.’s steady financial position and ongoing strategy to reward investors holding the Series A Preferred Stock. The dividend payout highlights confidence in the company’s future cash flow prospects. Market Overview…

Read More >>

Can-Fite BioPharma (NYSE American: CANF) Reports Study Validating Drug Potential for Canine Osteoarthritis

Expert Analysis The recent publication of a peer-reviewed article on Piclidenoson highlights a significant advancement for Can-Fite BioPharma (NYSE American: CANF). This research underlines the promising therapeutic effects of their drug candidate, Piclidenoson, in addressing canine osteoarthritis, a large and growing market with considerable medical need. The findings suggest that Piclidenoson’s mechanism as an A3 adenosine receptor agonist could provide a novel, effective treatment option. For Can-Fite BioPharma, these results…

Read More >>
x